Review of the epidemiological literature on antidepressant use and breast cancer risk

Expert Review of Neurotherapeutics

Volumn 6, Issue 9, 2006, Pages 1363-1374

  Coogan, Patricia F ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

Antidepressive agents; Breast cancer; Monoamine oxidase inhibitors; Pharmacoepidemiology; Selective serotonin uptake inhibitors; Tricyclic antidepressant agents

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; IMIPRAMINE; LOFEPRAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PROLACTIN; PYRIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

BREAST CANCER; BREAST TUMOR; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; FOOD AND DRUG ADMINISTRATION; GENOTOXICITY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; MEDICAL LITERATURE; PREVALENCE; PUBLIC HEALTH; REVIEW;

ANTIDEPRESSIVE AGENTS; BREAST NEOPLASMS; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; INCIDENCE; PERIODICALS; RISK ASSESSMENT; RISK FACTORS;

EID: 33750086346     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.9.1363     Document Type: Review

References (51)

1. Seki K, Nagata I. Effects of a dopamine antagonist (metoclopramide) on the release of LH, FSH, TSH and PRL in normal women throughout the menstrual cycle. Acta Endocrinol. (Copenh.) 122(2), 211-216 (1990).
2. Seki K, Uesato T, Kato K. Effects of a dopamine antagonist (metoclopramide) on the release of the adenohypophyseal hormones in amenorrhoeic patients with and without hyperprolactinaemia. Acta Endocrinol. (Copenh.) 101(2), 166-170 (1982).
3. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin. Proc. 80(8), 1050-1057 (2005).
4. Turkington RW. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch. Intern. Med. 130(3), 349-354 (1972).
5. Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 29(5), 833-846 (2004).
6. Cowen PJ, Sargent PA. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J. Psychopharmacol. 11(4), 345-348 (1997).
7. Welsch CW, Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res. 37(4), 951-963 (1977).
8. Hankinson SE, Willett WC, Michaud DS et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J. Natl Cancer Inst. 91(7), 629-634 (1999).
9. Brandes LJ, Arron RJ, Bogdanovic RP et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res. 52(13), 3796-3800 (1992).
10. Stafford RS, MacDonald EA, Finkelstein SN. National patterns of medication treatment for depression, 1987 to 2001. Prim. Care Companion J. Clin. Psychiatry 3(6), 232-235 (2001).
11. Pirraglia PA, Stafford RS, Singer DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim. Care Companion J. Clin. Psychiatry 5(4), 153-157 (2003).
12. Stagnitti MN. Trends in antidepressant use by the US civilian noninstitutionalized population, 1997 and 2002. Statistical Brief 76 from the Medical Expenditure Panel Survey. Agency for Healthcare Research and Quality, MD, USA (2005).
13. Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ. Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J. Exp. Ther. Oncol. 3(4), 169-184 (2003).
14. Danielson DA, Jick H, Hunter JR, Stergachis A, Madsen S. Nonestrogenic drugs and breast cancer. Am. J. Epidemiol. 116(2), 329-332 (1982).
15. Wallace RB, Sherman BM, Bean JA. A case-control study of breast cancer and psychotropic drug use. Oncology 39279-39283 (1982).
16. Friedman GD. RE: Depression, antidepressant medication, and cancer: an editor comments. Am. J. Epidemiol. 136(11), 1415-1416 (1992).
17. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res. 49(20), 5736-5747 (1989).
18. Kelly JP, Rosenberg L, Palmer JR et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am. J. Epidemiol. 150(8), 861-868 (1999).
19. Weiss SR, McFarland BH, Burkhart GA, Ho PT. Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressants. Clin. Pharmacol. Ther. 63(5), 594-599 (1998).
20. Ashbury FD, Madlensky L, Raich P et al. Antidepressant prescribing in community cancer care. Support. Care Cancer 11(5), 278-285 (2003).
21. Cullivan R, Crown J, Walsh N. The use of psychotropic medication in patients referred to a psycho-oncology service. Psychooncology 7(4), 301-306 (1998).
22. Fisch M, Callahan CM, Kesterson JG, Nichols C, Tierney WM. The use of an electronic patient record system to identify advanced cancer patients and antidepressant drug use. J. Palliat. Med. 2(4), 403-409 (1999).
23. Jaeger H, Morrow GR, Carpenter PJ, Brescia F. A survey of psychotropic drug utilization by patients with advanced neoplastic disease. Gen. Hosp. Psychiatry 7(4), 353-360 (1985).
24. Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication use and breast cancer risk. Am. J. Epidemiol. 151(10), 951-957 (2000).
25. Dalton SO, Johansen C, Mellemkjaer L et al. Antidepressant medications and risk for cancer. Epidemiology 11(2), 171-176 (2000).
26. Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE. Psychotropic medication use and risk of hormone-related cancers: the New York University Women's Health Study. J. Public Health Med. 22(2), 155-160 (2000).
27. Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J. Antidepressant use and the risk of breast cancer: a non-association. J. Clin. Epidemiol. 54(7), 728-734 (2001).
28. Sharpe CR, Collet JP, Belzile E, Hanley JA, Boivin JF. The effects of tricyclic antidepressants on breast cancer risk. Br. J. Cancer 86(1), 92-97 (2002).
29. van Schaik N, Graf U. Genotoxicity evaluation of five tricyclic antidepressants in the wing somatic mutation and recombination test in Drosophila melanogaster. Mutat. Res. 260(1), 99-104 (1991).
30. van Schaik N, Graf U. Structure-activity relationships of tricyclic antidepressants and related compounds in the wing somatic mutation and recombination test of Drosophila melanogaster. Mutat. Res. 286(2), 155-163 (1993).
31. Tamim H, Boivin JF, Hanley J, Stang M, Collet JP. Risk of breast cancer in association with exposure to two different groups of tricyclic antidepressants. Pharmacoepidemiol. Drug Saf. (2006) (E-pub ahead of print).
32. Moorman PG, Grubber JM, Millikan RC, Newman B. Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 14(3), 307-314 (2003).
33. Steingart A, Cotterchio M, Kreiger N, Sloan M. Antidepressant medication use and breast cancer risk: a case-control study. Int. J. Epidemiol. 32(6), 961-966 (2003).
34. Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR. Antidepressant use and breast cancer risk. Breast Cancer Res. Treat. 1-10 (2005).
35. Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am. J. Epidemiol. 162(9), 835-838 (2005).
36. Gonzalez-Perez A, Garcia Rodriguez LA. Breast cancer risk among users of antidepressant medications. Epidemiology 16(1), 101-105 (2005).
37. Haque R, Enger SM, Chen W, Petitti DB. Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett. 221(1), 61-65 (2005).
38. Ormandy CJ, Hall RE, Manning DL et al. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J. Clin. Endocrinol. Metab. 82(11), 3692-3699 (1997).
39. Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J. Steroid Biochem. Mol. Biol. 88(1), 69-77 (2004).
40. Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS. Use of antidepressant medications in relation to the incidence of breast cancer. Br. J. Cancer 94(7), 1071-1078 (2006).
41. Bahl S, Cotterchio M, Kreiger N. Use of antidepressant medications and the possible association with breast cancer risk. A review. Psychother. Psychosom. 72(4), 185-194 (2003).
42. Lawlor DA, Juni P, Ebrahim S, Egger M. Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J. Clin. Epidemiol. 56(2), 155-163 (2003).
43. Jurek AM, Greenland S, Maldonado G, Church TR. Proper interpretation of non-differential misclassification effects: expectations vs observations. Int. J. Epidemiol. 34(3), 680-687 (2005).
44. Cotterchio M, Kreiger N, Darlington G, Steingart A. Comparison of self-reported and physician-reported antidepressant medication use. Ann. Epidemiol. 9(5), 283-289 (1999).
45. Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am. J. Epidemiol. 159(3), 308-317 (2004).
46. Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet 345(8942), 99-103 (1995).
47. Penninx BW, Guralnik JM, Pahor M et al. Chronically depressed mood and cancer risk in older persons. J. Natl Cancer Inst. 90(24), 1888-1893 (1998).
48. Persky VW, Kempthorne-Rawson J, Shekelle RB. Personality and risk of cancer: 20-year follow-up of the Western Electric Study. Psychosom. Med. 49(5), 435-449 (1987).
49. Dalton SO, Mellemkjaer L, Olsen JH, Mortensen PB, Johansen C. Depression and cancer risk: a register-based study of patients hospitalized with affective disorders, Denmark, 1969-1993. Am. J. Epidemiol. 155(12), 1088-1095 (2002).
50. Hjerl K, Andersen EW, Keiding N et al. Breast cancer risk among women with psychiatric admission with affective or neurotic disorders: a nationwide cohort study in Denmark. Br. J. Cancer 81(5), 907-911 (1999).
51. Lillberg K, Verkasalo PK, Kapr J, Teppo L, Helenius H, Koskenvuo M. A prospective study of life satisfaction, neuroticism and breast cancer risk (Finland). Cancer Causes Control 13(2), 191-198 (2002).